1. Scrip
  2. >>Business

BioNTech and MediLink’s HER3 ADC Back In The Game After Safety Concerns

 
• By Andrew McConaghie

The partners still believe their HER3-targeting ADC can rival Merck & Co and Daiichi Sankyo’s frontrunner, even at a new lower dose range.

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags
• Source: Florian Imbusch / Shutterstock.com

BioNTech and MediLink Therapeutics will resume enrolment in a Phase I study of their antibody-drug conjugate, BNT326, in lung and breast cancer patients after a partial hold related to treatment-related deaths was lifted.

BNT326/YL202 is a human epidermal growth factor receptor 3 (HER3)-targeting antibody-drug conjugate (ADC) candidate, a field as yet with no approved treatments, but where competition is hotting up (see table).

Key Takeaways

  • BioNTech and MediLink can resume Phase I recruitment again, but have lowered the dose after three deaths were recorded.

  • Data presented at ASCO suggested...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback